Guardant Health’s (GH) Outperform Rating Reaffirmed at Raymond James
Raymond James reaffirmed their outperform rating on shares of Guardant Health (NASDAQ:GH – Free Report) in a research note published on Friday morning,Benzinga reports. They currently have a $59.00 price objective on the stock, up from their prior price objective of $39.00. Several other brokerages also recently weighed in on GH. Barclays initiated coverage on […]
Raymond James reaffirmed their outperform rating on shares of Guardant Health (NASDAQ:GH – Free Report) in a research note published on Friday morning,Benzinga reports. They currently have a $59.00 price objective on the stock, up from their prior price objective of $39.00. Several other brokerages also recently weighed in on GH. Barclays initiated coverage on […]
